StockNews.AISignal intelligence
Company intelligence

ZTS

Zoetis Inc. · NYSE · Healthcare

Price$83.82+1.04% · +$0.86
Market cap34.06BEquity value
P / E12.7Trailing ratio
Volume3.11MLatest session
Market data

ZTS price chart

TradingView
Related signals
1 min delayed

Browse public ZTS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ZTSNov 5, 2026-4.41% since signal

Zoetis guides cautiously for 2027 amid softer pet-care demand

Zoetis said it will guide conservatively for 2027 as pet owners scale back discretionary vet visits, pressuring near-term revenue prospects. The muted outlook followed a period of robust growth and shares fell on the news, highlighting investor concerns about demand elasticity in routine veterinary services. The key question is whether demand improves into 2027 or remains restrained.

View signal analysis
ZTSNov 5, 2026-4.07% since signal

Zoetis Q3 Beat Trims 2026 Guidance; Longer-Term Upside From 2027–2028 Launches

Zoetis topped Q3 expectations with EPS of $1.75 on $2.391B revenue, beating estimates. U.S. Companion Animal weakness offset by Livestock and Diagnostics growth. The company raised its 2026 adjusted EPS to $6.25-$6.35 and 2026 sales to $9.22B-$9.32B, signaling confidence despite ongoing vet-visit and price-headwinds. Shares fell about 6% on the results, with longer-term upside tied to 2027-2028 launches.

View signal analysis
ZTSAug 13, 2026-1.44% since signal

FDA EUA for Zoetis NWS treatment signals near-term ZTS revenue potential

The FDA granted emergency use authorization for Zoetis' flea and tick product to combat New World screwworm infestations in dogs and puppies. This regulatory endorsement could unlock short-term demand for Zoetis' veterinary portfolio and may lift sentiment around ZTS, particularly within pet-health offerings. The impact will depend on patient access, supply, and broader adoption.

View signal analysis
ZTSAug 6, 2026-2.72% since signal

Zoetis cuts full-year guidance after Q2 miss; implications for ZTS

Zoetis reported a Q2 revenue miss and cut its full-year forecast as softer demand for pet healthcare products and heightened competition weigh on the business. The revision signals near-term earnings pressure and potential multiple re-rating if visibility on pricing and cost controls remains weak, making near-term risk-off sentiment likely for ZTS holders.

View signal analysis
Research

Company intelligence